メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:黒色腫 (メラノーマ) の疫学的予測 (〜2023年)

EpiCast Report: Melanoma - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 331729
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
EpiCast Report:黒色腫 (メラノーマ) の疫学的予測 (〜2023年) EpiCast Report: Melanoma - Epidemiology Forecast to 2026
出版日: 2017年10月03日 ページ情報: 英文 30 Pages
概要

世界の主要8カ国 (米国・フランス・ドイツ・イタリア・スペイン・英国・日本・オーストラリア) における黒色腫 (メラノーマ) の診断症例数は、2013年から2023年にかけて3.39%の年成長率で推移し、2013年の155,057件から2023年には207,606件に達すると予測されています。また、主要8ヶ国における5カ年の累積有病者数は2013年の639,165件から2023年までに860,889件へ拡大する見込みです。

当レポートでは、世界の主要8カ国における黒色腫 (メラノーマ) の診断症例数および死亡者数の推移について調査し、疾患の背景、リスク要因と併存症、年齢・性別・重篤度・原因病原別の診断症例数および死亡者数の予測などについてまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク要因と併存症
  • 世界の動向
    • 米国
    • EU5カ国
    • 日本・オーストラリア
  • 予測手法
    • 使用ソース
    • 未使用ソース
    • 予測の前提条件・手法
  • 黒色腫 (メラノーマ) の疫学的予測
    • 診断症例数
    • 診断症例数:年齢別
    • 診断症例数:性別
    • 標準診断事例の割合:年齢別
    • 診断における病期
    • 5カ年の有病者数
    • 5カ年の有病者数:遺伝子異常
  • 検証
    • 疫学的予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

目次
Product Code: GDHCER161-17

Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013).

In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagnosed prevalent cases of melanoma in the 7MM are also expected to increase from almost 0.75 million cases in 2016 to over 900,000 cases in 2026 at an AGR of over 2.5%.

Australia has the highest age-standardized incidence rate of melanoma in the 7MM by a significant margin. In 2016, incidence of melanoma in Australian men was over 60 cases per 100,000, and over 41.59 cases per 100,000 in Australian women. The second highest age-standardized incidence of melanoma in men was in the US, at about 30 cases per 100,000 of its population. The UK had the second highest incidence rate in women, at about 20 cases per 100,000. Over the forecast period, the age-standardized incidence rates of melanoma will remain largely unchanged, with the greatest growth seen in Germany from 2006-2011.

The report "EpiCast Report: Melanoma - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).

Scope

  • The Melanoma EpiCast Report provides an overview of the risk factors and global trends of melanoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).
  • The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Melanoma EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for melanoma therapeutics in each of the markets covered.
  • Compare patient population potentials by age, sex, stage at diagnosis, and survival.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Melanoma: Executive Summary 4

  • 2.1 Related Reports 7
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 14
  • 3.5 Epidemiological Forecast for Melanoma (2016-2026) 18
    • 3.5.1 Diagnosed Incident Cases of Melanoma 18
    • 3.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 20
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma 21
    • 3.5.4 Five-Year Diagnosed Prevalent Cases of Melanoma 21
    • 3.5.5 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis 23
  • 3.6 Discussion 23
    • 3.6.1 Epidemiological Forecast Insight 23
    • 3.6.2 Limitations of Analysis 24
    • 3.6.3 Strengths of Analysis 24

4 Appendix 25

  • 4.1 Bibliography 25
  • 4.2 About the Authors 28
    • 4.2.1 Epidemiologist 28
    • 4.2.2 Reviewers 28
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 29
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 29
  • 4.3 About GlobalData 30
  • 4.4 Contact Us 30
  • 4.5 Disclaimer 30

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors for Melanoma of the Skin 9
  • Table 2: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 19
  • Table 3: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 22

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 5
  • Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2006-2026 10
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2006-2026 11
  • Figure 5: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016 12
  • Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016 13
  • Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016 14
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016 20
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages ≥18 Years, 2016 21
  • Figure 10: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages ≥18 Years, 2016 23
Back to Top